Zai Lab Ltd (ZLAB): Cash & Equivalents
$679.57M
As of 2025-12-31
$607.52M
As of 2026-06-30
-12.3%
3-year compound annual growth
+9.0%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $679.57M | +51.1% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $449.67M | -43.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $790.15M | -21.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $1.01B | +4.6% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $964.10M | +118.1% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $442.12M | +482.3% | 2023-03-01, Balance as of period end |
| 2019-12-31 | $75.93M | +20.6% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $62.95M | -72.6% | 2021-03-01, Balance as of period end |
| 2017-12-31 | $229.66M | +173.6% | 2020-04-29, Balance as of period end |
| 2016-12-31 | $83.95M | +537.9% | 2019-03-29, Balance as of period end |
| 2015-12-31 | $13.16M | n/a | 2018-04-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $679.57M | +51.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $93.03M | +58.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $570.12M | -16.3% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $550.94M | +80.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $68.00M | +4.7% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $296.68M | +33.3% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $488.25M | +45.6% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $71.33M | -53.7% |
Compare ZLAB, NATR, TVTX, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗